MediBeacon
12
2
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
25%
3 trials in Phase 3/4
38%
3 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Evaluation of Protein Loading on Measurement of Renal Reserve
Role: lead
MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure
Role: lead
Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic Surgeries
Role: lead
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Role: lead
Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
Role: lead
Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
Role: lead
A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants
Role: collaborator
Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
Role: lead
Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability
Role: lead
Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System
Role: lead
Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers
Role: lead
Pharmacokinetics of MP-3180 in Healthy Volunteers
Role: lead
All 12 trials loaded